Meiragtx Holdings (MGTX) AI Stock Analysis

• Market Cap: $453.42M
• Dividend Yield: N/A
• Average Volume (3M): 757.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.09
• Revenue Growth: 137.42%
• EPS Growth: -34.13%
• Country: US
• Employees: 375
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -2.13
• Shares Outstanding: 78,854,935
• 10 Day Avg. Volume: 749,568
• 30 Day Avg. Volume: 757,654
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 17.91
• Price to Cash Flow (P/CF): -6.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $19.50
• Price Target Upside: 272.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Meiragtx Holdings' stock score reflects its strong revenue growth juxtaposed with significant profitability challenges and cash flow issues. The recent joint venture with Hologen provides a positive outlook and financial support, but the company's negative valuation metrics and neutral technical indicators suggest cautious optimism. Improvement in operational efficiency and sustained cash flow generation are critical for future performance.

Meiragtx Holdings Business Overview & Revenue Model

Company Description

MeiraGTx Holdings Plc (MGTX) is a clinical-stage gene therapy company focused on developing and commercializing innovative treatments for patients suffering from serious diseases. The company operates in the biotechnology sector, with a pipeline of gene therapy candidates targeting a range of conditions including inherited retinal diseases, neurodegenerative disorders, and severe forms of xerostomia. MeiraGTx is dedicated to advancing its proprietary technology platforms to address unmet medical needs through the development of transformative therapies.

How the Company Makes Money

MeiraGTx Holdings primarily generates revenue through strategic collaborations and partnerships with larger pharmaceutical companies. These agreements often include upfront payments, milestone payments, and royalties on any commercialized products developed from their collaborative efforts. Additionally, the company may receive funding for its research and development activities from grants and other non-dilutive sources. As a clinical-stage company, MeiraGTx is focused on advancing its pipeline through clinical trials, with the goal of eventually obtaining regulatory approval and commercializing its therapies, which would allow it to generate direct sales revenue from marketed products.

Meiragtx Holdings Financial Statement Overview

Summary

Meiragtx Holdings demonstrates strong revenue growth but faces significant profitability challenges, with persistent losses impacting financial health. While the balance sheet shows low leverage, the company struggles with cash flow generation, raising concerns about its ability to sustain operations without additional financing. Strategic initiatives to improve operational efficiency and reduce costs are essential for future stability.

Income Statement

Meiragtx Holdings has shown significant revenue growth from $14.0M to $33.3M in 2024, indicating a strong top-line performance. However, the company remains unprofitable with a negative net profit margin of -444.2% and declining EBIT and EBITDA margins, reflecting substantial operating losses.

Balance Sheet

The company's balance sheet shows a favorable debt-to-equity ratio of 0.06, indicating low leverage. However, the equity ratio has declined to 25.1%, suggesting reduced equity financing. The company's return on equity is negative due to persistent net losses, indicating inefficiency in generating profits from shareholders' equity.

Cash Flow

Meiragtx Holdings continues to experience negative free cash flow of -$109.5M, with limited improvement in free cash flow growth. The operating cash flow to net income ratio is negative, suggesting operational inefficiencies and challenges in converting earnings into cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
33.28M	14.02M	15.92M	37.70M	15.56M
	Gross Profit
9.49M	14.02M	7.20M	29.83M	15.56M
	EBIT
-164.21M	-137.06M	-116.36M	-73.19M	-62.55M
	EBITDA
-121.84M	-57.05M	-115.95M	-71.40M	-53.68M
	Net Income Common Stockholders
-147.79M	-84.03M	-142.88M	-71.98M	-53.96M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
103.66M	129.57M	115.52M	137.70M	209.52M
	Total Assets
269.75M	326.74M	318.24M	320.16M	363.70M
	Total Debt
4.05M	89.26M	92.25M	23.73M	22.25M
	Net Debt
-99.61M	-40.30M	-23.27M	-113.97M	-187.27M
	Total Liabilities
201.92M	188.57M	200.50M	134.76M	125.14M
	Stockholders Equity
67.83M	138.18M	117.74M	185.40M	238.56M
Cash Flow		Free Cash Flow
-109.45M	-125.54M	-118.06M	-65.75M	-100.99M
	Operating Cash Flow
-104.50M	-105.36M	-73.10M	-10.53M	-63.97M
	Investing Cash Flow
23.48M	34.03M	-44.96M	-61.72M	-37.02M
	Financing Cash Flow
54.53M	84.02M	95.20M	1.71M	82.73M

Meiragtx Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Negative. The current price of 5.24 is below the 20-day moving average (MA) of 7.02, below the 50-day MA of 6.80, and below the 200-day MA of 5.58, indicating a bearish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 38.17 is Neutral, neither overbought nor oversold. The STOCH value of 15.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGTX.

Meiragtx Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RGNX	56 Neutral	$297.01M	―	-79.49%	―	-7.66%	23.04%
ADPT	49 Neutral	$1.14B	―	-62.41%	―	5.10%	30.45%
Sector *	48 Neutral	$6.36B	1.24	-44.94%	2.70%	18.33%	1.47%
CRSP	46 Neutral	$2.79B	―	-19.20%	―	-89.95%	-123.71%
MGTX	45 Neutral	$453.42M	―	-143.48%	―	137.42%	-34.13%
NTLA	41 Neutral	$677.00M	―	-54.00%	―	59.55%	3.09%
EDIT	39 Underperform	$82.98M	―	-98.10%	―	-58.64%	-40.05%

Meiragtx Holdings Corporate Events

MeiraGTx Holdings Signs New Lease in New York

On March 31, 2025, MeiraGTx, LLC, a subsidiary of MeiraGTx Holdings plc, entered into a lease agreement with ARE-East River Science Park, LLC for laboratory and office space in New York, NY. The lease is set to commence between July 1 and August 1, 2025, with an initial term of seven years and seven months, and includes an option for a five-year extension. The agreement involves a base rent of $111 per square foot per year, with scheduled annual increases, and a landlord contribution for construction and improvements. Additionally, MeiraGTx has decided to accelerate the termination of its existing sublease with ImClone Systems, LLC, which will now end around August 31, 2025, instead of the originally scheduled October 31, 2026.

MeiraGTx Holdings Announces Joint Venture with Hologen

On March 9, 2025, MeiraGTx Holdings announced a strategic collaboration with Hologen Limited, a leader in generative AI models for clinical medicine, to form a joint venture called Hologen Neuro AI Ltd. This partnership aims to expedite the development of MeiraGTx’s AAV-GAD gene therapy for Parkinson’s disease and other CNS therapies, with Hologen providing up to $230 million in funding. MeiraGTx will receive $200 million upfront and retain a 30% stake in the joint venture, while Hologen will own a minority stake in MeiraGTx’s manufacturing subsidiary. The collaboration is expected to enhance MeiraGTx’s manufacturing capabilities and extend its cash runway, potentially accelerating other programs such as the AAV-hAQP1 Xerostomia program.